FDA granted orphan drug designation to Sanofi's drug on July 6, 2025.
2 reports, 0 independent
Updated Jul 6
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted orphan drug designation to Sanofi's drug on July 6, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- FDA granted Orphan Drug Designation to BRC's drug.
- The FDA granted Orphan Drug Designation to sovleplenib, a drug associated with HUTCHMED, which operates in China.
- BioTech generated encouraging early data for MASH and POTS, and expects an FDA decision regarding cemdisiran next month.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- FDA approved a drug based on UVA research led by Xuemei Huang.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet